Us Congress House Bill HB1768

Us Congress 2025-2026 Regular Session

• Introduced: 3/3/25
• Refer: 3/3/25

Caption

Lower Costs for Everyday Americans Act Nationwide Consumer and Fuel Retailer Choice Act Recycling and Composting Accountability Act SUPPORT for Patients and Communities Reauthorization Act of 2025 American Music Tourism Act Deploying American Blockchains Act

Impact

If enacted, HB 1768 will significantly impact state laws related to healthcare pricing and the functioning of pharmacy benefit managers (PBMs). The legislation expects to create a more competitive landscape that incentivizes reduced drug prices for consumers while ensuring that pharmacies are adequately compensated for their services. By enforcing transparency requirements, the bill seeks to promote accountability amongst PBMs and health plans, enabling consumers to make more informed decisions about their medication options.

Summary

House Bill 1768 addresses several critical aspects of healthcare, primarily focusing on increasing transparency in prescription drug pricing and pharmacy benefit management services. The bill mandates that entities providing pharmacy benefit management services must remit 100% of rebates and fees received from drug utilization back to group health plans. This aims to ensure that healthcare costs are not unnecessarily inflated due to undisclosed rebates, thereby benefiting consumers directly. This requirement is projected to improve cost-effectiveness in drug pricing and enhance transparency in how drug costs are managed by insurers and benefit managers.

Contention

Debates surrounding HB 1768 have highlighted concerns regarding the balance between affordability and maintaining sufficient access to pharmacy services. Supporters argue that the bill's provisions will curb excessive costs imposed by PBMs and consequently lower consumer healthcare expenses. Conversely, opponents warn that the stringent requirements may lead to reduced negotiation power for PBMs, potentially resulting in higher prices for patients if the market dynamics shift unfavorably. As the bill progresses through legislative discussions, both sides continue to raise valuable points regarding its implications for future healthcare access and affordability.